Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by tboron Sep 11, 2007 4:31pm
269 Views
Post# 13376372

RE: AGM TOMORROW - stockgambler

RE: AGM TOMORROW - stockgamblerStockgambler, I believe that scuba00 was asking "what if?" "What if they put out a NR ect ect" His original post is as follows: "Here is a scenerio that I would like people's ideas on: RVX as a Company, comes out and says all negotiations have been put on hold until the end of phase I trials. It is the Company's belief that the fair value of the stock price is significantly under valued, the 3rd party UBS agrees with us. In our talks with at least 4 different pharmas, the value of our Company has numerously been discussed with no actually term sheet being given. With our shareholders in mind, we believe the stock price will increase substancally by cutting off negotiations for the time being, thus allowing us to give the actual dollar per share amount that we believe and what UBS believes should be. It is also our belief that phase I trials through data that has already been collected will turn out very positive. Wouldn't this scenerio positively reflect the share price , it would also give insiders a chance to buy up cheap shares. It would also allow people to focus on the drug not the sale. If a Pharma is seriously interested this would not deter from giving a term sheet, obviously they should already know what Don wants. And if they really do want to make an offer they couldn't care a less if the Company wants to or not. Any thoughts?"
Bullboard Posts